Role of azathioprine in preventing recurrences in a patient of recurrent erythema nodosum leprosum

Leprosy Review

Volumn 77, Issue 3, 2006, Pages 225-229

  Verma, Kaushal K ^a   Srivastava, P ^a   Minz, Anil ^a   Verma, Kamna ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLOFAZIMINE; PREDNISOLONE; THALIDOMIDE;

ADOLESCENT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ELECTROPHYSIOLOGY; ERYTHEMA NODOSUM LEPROSUM; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDIA; LABORATORY TEST; MULTIBACILLARY LEPROSY; RECURRENT DISEASE; SKIN BIOPSY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADOLESCENT; AZATHIOPRINE; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA NODOSUM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; RECURRENCE;

EID: 33845417155     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lockwood DNJ. The management of erythema nodosum leprosum: current and future options. Lepr Rev, 1996; 67: 253-259.
2. Wemambu SN, Turk JL, Waters MFR, Rees RJW. Erythema nodosum leprosum, a clinical manifestation of the arthus phenomenon. Lancet, 1969; ii: 933-935.
3. Ridley MJ, Ridley DS. The immunopathology of eythema nodosum leprosum: the role of extravascular complexes. Lepr Rev, 1983; 54: 95-97.
4. Abalos RM, Tolentino JG, Bustillo CG. Histochemical study of erythema nodosum leprosum (ENL) lesions. Int J Lepr, 1974; 42: 385-391.
5. Modlin RL, Gebhard JF, Trylor CR, Rea TH. In-situ characterization of T-ymphocyte subsets in the reactional states of leprosy. Clin Exp Immunol, 1983; 53: 17-24.
6. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1b during leprosy reactional states. Clin Exp Immunol, 1991; 84: 103-108.
7. Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol, 1968; 14: 161-177.
8. Salmaggi A, Corsini E, La Mantia L, et al. Immunological monitoring of azathioprine treatment in multiple sclerosis patients. J Neurol, 1997; 244: 167-174.
9. Mahajan VK, Sharma NL, Sharma RC, Sharma A. Pulse dexamethasone, oral steroids and azathioprine in the management of erythema nodosum leprosum. Lepr Rev, 2003; 74: 171-174.
10. Marlowe SNS, Hawksworth RA, Butlin CR, Nicholls PG, Lockwood DNJ. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe type 1 reactions in Nepal. Trans R Soc Tropical Med Hyg, 2004; 98: 602-609.
11. Verma KK, Manchanda Y, Pasricha JS. Azathioprine as a corticosteroid sparing agent for the treatment of dermatitis caused by the weed parthenium. Acta Derm Venerol, 2000; 80: 31-32.
12. Verma KK, Manchanda Y. Long-term safety and toxicity of azathioprine in patients with air-borne contact dermatitis. Ind J Dermatol Venereol Leprol, 2001; 67: 75-77.